Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Income: 2009-2024

Historic Non Operating Income for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$27.9 million.

  • Ironwood Pharmaceuticals' Non Operating Income rose 9.71% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.6 million, marking a year-over-year decrease of 7.10%. This contributed to the annual value of -$27.9 million for FY2024, which is 129.90% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Non Operating Income of -$27.9 million as of FY2024, which was down 129.90% from $93.4 million recorded in FY2023.
  • Ironwood Pharmaceuticals' Non Operating Income's 5-year high stood at $93.4 million during FY2023, with a 5-year trough of -$34.1 million in FY2020.
  • Its 3-year average for Non Operating Income is $22.5 million, with a median of $2.1 million in 2022.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Non Operating Income surged by 4,379.33% in 2023, and later crashed by 129.90% in 2024.
  • Ironwood Pharmaceuticals' Non Operating Income (Yearly) stood at -$34.1 million in 2020, then grew by 7.27% to -$31.6 million in 2021, then spiked by 106.60% to $2.1 million in 2022, then surged by 4,379.33% to $93.4 million in 2023, then tumbled by 129.90% to -$27.9 million in 2024.